Principles of Rational Haemotherapy Interdisciplinary Consensus Statement
Authors:
M. Bohoněk, (STL) 1,2; J. Bláha, (ČSARIM, ČSIM, ČSTH) 3; A. Buliková, (ČHS) 4,5; R. Češka, (ČIS) 6; J. Gumulec, (ČSTH) 7; Z. Kala, (ČCHS) 8; T. Kuhn, (ČPS*) 9; Luboš Kotík, (ČIS) 10; J. Masopust, (STL) 11; J. Malý, (ČNeoS) 12; P. Mazánek, (ČPS*) 13; R. Procházková, (STL) 14,15; Martin Repko, (ČSOT) 16; A. Truhlář, (SUMMK) 17,18; M. Tuček, (ČSOT) 19; K. Zdráhalová, (ČHS) 20; P. Žák, (ČHS) 21
Authors‘ workplace:
Ústav laboratorní medicíny, hematologie a transfuziologie FBMI ČVUT a ÚVN, Oddělení hematologie a krevní transfuze, ÚVN – VFN Praha
1; Fakulta biomedicínského inženýrství, ČVUT Praha
2; Klinika anesteziologie, resuscitace a intenzivni mediciny, 1. LF UK a VFN v Praze
3; Oddělení klinické hematologie, FN Brno
4; Interní hematologická a onkologická klinika LF MU, Brno
5; III. interní klinika-klinika endokrinologie a metabolismu 1. LF UK a VFN v Praze
6; Klinika hematologie LF OU a FN Ostrava
7; Chirurgická klinika LF MU a FN Brno
8; Klinika dětského lékařství FN Ostrava
9; Interní klinika FTN Praha
10; Transfuzní oddělení, KZ, a. s., Masarykova nemocnice v Ústí nad Labem, o. z.
11; Dětská klinika LF UK a FN Hradec Králové
12; Oddělení dětské hematologie a biochemie, FN Brno
13; Transfuzní oddělení, Krajská nemocnice Liberec, a. s.
14; Fakulta zdravotnických studií, Technická univerzita v Liberci
15; Ortopedická klinika LF MU a FN Brno
16; Zdravotnická záchranná služba Královéhradeckého kraje, Hradec Králové
17; Klinika anesteziologie, resuscitace a intenzívní medicíny LF UK a FN Hradec Králové
18; Klinika ortopedie 1. LF UK a ÚVN – VFN Praha
19; Klinika dětské hematologie a onkologie 2. LF UK a FNMH – Motol
20; IV. interní hematologická klinika LF UK a FN Hradec Králové
21
Published in:
Transfuze Hematol. dnes,32, 2026, No. 1, p. 54-64.
Category:
Best Practices
doi:
https://doi.org/10.48095/cctahd202608
Overview
The administration of blood and blood products requires careful indication and procedures with regard to maximizing the effectiveness of transfusion therapy while minimizing known risks. We present consensus-based interdisciplinary recommendations on the principles of rational hemotherapy as best practices for the indication and administration of blood products.
Keywords:
Patient Blood Management – rational haemotherapy – blood products
Sources
1. Mueller MM, Van Remoortel H, Meybohm P, et al. Patient blood management: recommendations from the 2018 Frankfurt Consensus Conference. JAMA. 2019; 321 (10): 983–997.
2. https: //www.bloodcomponents.org.uk.
3. Treleaven J, Gennery A, Marsh J, et al. Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force. Br J Haematol. 2011; 152 : 35–51.
4. Squizzato A, Hunt BJ, Kinasewitz BT, et al. Supportive management strategies for disseminated intravascular coagulation, An international consensus. Throm Haemost. 2016; 115 (5): 896–904.
5. Liu P, Hum J, Jou J, Scanlan RM, Shatzel J. Transfusion strategies in patients with cirrhosis. Eur J Haematol. 2020; 104 : 15–25.
6. Kirpalani H, Bell EF, Hintz SR, et al. Eunice Kennedy Shriver NICHD Neonatal Research Network. Higher or lower hemoglobin transfusion thresholds for preterm infants. N Engl J Med. 2020; 383 (27): 2639–2651. doi: 10.1056/NEJMoa2020248.
7. Franz AR, Engel C, Bassler D, et al. Effects of liberal vs restrictive transfusion thresholds on survival and neurocognitive outcomes in extremely low-birth-weight infants: The ETTNO randomized clinical trial. JAMA. 2020; 324 (6): 560–570. doi: 10.1001/jama.2020.10690. Erratum in: JAMA. 2022; 328 (2): 217.
8. Howarth C, Banerjee J, Aladangady N. Red blood cell transfusion in preterm infants: current evidence and controversies. Neonatology. 2018; 114 (1): 7–16. doi: 10.1159/000 486584.
9. Villeneuve A, Arsenault V, Lacroix J, Tucci M. Neonatal red blood cell transfusion. Vox Sang. 2021; 116 (4): 366–378. doi: 10.1111/vox. 13036.
10. Ohls R. Red blood cells transfusions in the newborn. Dostupné na https: //www.uptodate.com/contents/red-blood-cell-rbc-transfusions-in-the-neonate
11. New HV, Berryman J, Bolton-Maggs PH, et al. British Committee for Standards in Haematology. Guidelines on transfusion for fetuses, neonates and older children. Br J Haematol. 2016; 175 (5): 784–828. doi: 10.1111/bjh.14233.
12. New HV, Grant-Casey J, Lowe D, et al. Red blood cell transfusion practice in children: current status and areas for improvement? A study of the use of red blood cell transfusions in children and infants. Transfusion. 2014; 54 (1): 119–127. doi: 10. 1111/trf. 12313.
13. O‘Brien SH, Badawy SM, Rotz SJ, et al. The ASH-ASPHO choosing wisely campaign: 5 hematologic tests and treatments to question. Blood Adv. 2022; 6 (2): 679–685. doi: 10.1182/bloodadvances.2020003635.
14. Foukaneli T, Kerr P, Bolton-Maggs PHB, et al. BCSH Committee. Guidelines on the use of irradiated blood components. Br J Haematol. 2020; 191 (5): 704–724. doi: 10.1111/bjh. 17015.
15. King KE, Ness PM. How do we prevent transfusion-associated graft-versus-host disease in children? Transfusion. 2011; 51 (5): 916–920. doi: 10.1111/j.1537-2995.2010.03011.x.
16. Nellis ME, Goel R, Karam O. Transfusion management in pediatric oncology patients. Hematol Oncol Clin North Am. 2019; 33 (5): 903–913. doi: 10.1016/j.hoc.2019.05.011.
17. Granulocyte Working Group. Clinical guidelines for the use of granulocyte transfusion, Blood and Transplant, Revised by S. Morton & S. Stanworth, 2021.
18. Ohsaka A, Kikuta A, Ohto H, et al. Guidelines for safety management of granulocytes transfusion in Japan. Int J Hematol. 2010; 91 : 201–208.
19. New HV, Berryman J, Bolton-Maggs PH, et al. British Committee for Standards in Haematology. Guidelines on transfusion for fetuses, neonates and older children. Br J Haematol. 2016; 175 (5): 784–828. doi: 10.1111/bjh.14233.
20. Wlodarski MW, Vlachos A, Farrar JE, et al. Diagnosis, treatment, and surveillance of Diamond-Blackfan anaemia syndrome: international consensus statement. Lancet Haematol. 2024; 11 (5): e368–e382.
21. Curley A, Stanworth SJ, Willoughby K, et al. Randomized trial of platelet-transfusion thresholds in neonates. N Engl J Med. 2019; 380 (3): 242–251. doi: 10.1056/NEJMoa1807320.
22. Fustolo-Gunnink SF, Fijnvandraat K, van Klaveren D, et al. Preterm neonates benefit from low prophylactic platelet transfusion threshold despite varying risk of bleeding or death. Blood. 2019; 134 (26): 2354–2360. doi: 10.1182/blood.2019000899. Erratum in: Blood. 2020; 135 (24): 2199. doi: 10.1182/blood.2020 006498.
23. Hasan R, Saifee NH. Benefits of lower neonatal platelet transfusion thresholds. Transfusion. 2021; 61 (6): 1672–1675. doi: 10.1111/trf. 16386.
24. New HV, Berryman J, Bolton-Maggs PH, et al. British Committee for Standards in Haematology. Guidelines on transfusion for fetuses, neonates and older children. Br J Haematol. 2016; 175 (5): 784–828. doi: 10.1111/bjh. 14233.
25. Houben NAM, Lopriore E, Fijnvandraat K, et al. Platelet transfusion in neonatal intensive care units of 22 European countries: a prospective observational study. Lancet Regional Health – Europe. 2024; 47 : 101086. DOI: 10.1016/j.lanepe.2024.101086.
26. Zerra PE, Josephson C. Transfusion in the neonatal patient: review of evidence based guidelines. Clin Lab Med. 2021; 41 (1): 15–34.
27. Christensen RD, Bahr TM, Davenport P, et al. Implementing evidence-based restrictive neonatal intensive care unit platelet transfusion guidelines. J Perinatol. 2024; 44 : 1394–1401.
28. Orkin SH, Nathan DG, Ginsburg D, Look AT, Fischer DE, Lux SE eds. Nathan and Oski‘s Hematology and Oncology of Infancy and Childhood. Elsevier Health Sciences, 2014.
Do redakce doručeno dne: 7. 11. 2025.
Přijato dne: 11. 11. 2025.
MUDr. Miloš Bohoněk, Ph.D.
Ústav laboratorní medicíny, hematologie a transfuziologie FBMI ČVUT
Oddělení hematologie a krevní transfuze
ÚVN – VFN Praha
U Vojenské nemocnice 1200
169 02 Praha 6
e-mail: milos.bohonek@uvn.cz
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2026 Issue 1
- Minimum and Optimal Factor Levels in Physically Active Hemophiliacs
- What FVIII Levels Are Ideal for Preventing Bleeding in Hemophilia A?
- The Importance of Hydration in Wound Healing
- Cost Effectiveness of FVIII Substitution Versus Non-Factor Therapy for Hemophilia A
- Vascular Disease in the Gradually Aging Population of Hemophiliacs: An Underestimated Problem?
-
All articles in this issue
- Venetoklax – základ neintenzivní cílené léčby akutní myeloidní leukémie
- Acute myeloid leukaemia – how the approach to diagnosis, risk stratification, and treatment options has changed
- Venetoclax plus azacitidine as a bridge treatment to allogeneic stem cell transplantation in acute myeloid leukaemia patients
- What can be expected from venetoclax + azacitidine (VEN+AZA) in acute myeloid leukaemia (AML) – results from VIALE-A and post-hoc analyses
- Antifungal prophylaxis in patients with acute myeloid leukaemia treated with venetoclax and azacitidine
- Treatment of multiple myeloma with manifestations of light chain deposition disease; complete remission with minimal residual disease negativity following treatment with daratumumab, dexamethasone, and lenalidomide – a case report and a review of the literature
- Concurrent occurrence of BCR:: ABL1-positive chronic myeloid leukaemia and Philadelphia-negative myeloproliferative neoplasm
- Principles of Rational Haemotherapy Interdisciplinary Consensus Statement
- Recommendation of the Society for Transfusion Medicine No. 20 Cold red blood cell antibodies testing before cardiothoracic surgery on cardiopulmonary bypass
- 18. Střešovický transfuzní den
- Zanubrutinib čtyřikrát jinak v klinické praxi
- Hodgkinův lymfom – klíčová sdělení z ASH 2025
- Transfusion and Haematology Today
- Journal archive
- Current issue
- Online only
- About the journal
Most read in this issue
- Principles of Rational Haemotherapy Interdisciplinary Consensus Statement
- Acute myeloid leukaemia – how the approach to diagnosis, risk stratification, and treatment options has changed
- Treatment of multiple myeloma with manifestations of light chain deposition disease; complete remission with minimal residual disease negativity following treatment with daratumumab, dexamethasone, and lenalidomide – a case report and a review of the literature
- What can be expected from venetoclax + azacitidine (VEN+AZA) in acute myeloid leukaemia (AML) – results from VIALE-A and post-hoc analyses